/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TSX VENTURE EXCHANGE: AVI
TORONTO, March 10 /CNW/ - Bio-Processing Alliance Inc. announces its official launch of business. BPAI is a biologics drug development 'think tank' providing consultative direction and support in the management of complex biologics programs from concept, through to development and
TORONTO, March 10 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced the appointment of Mr. Kevin Giese, President, CEO and Director of BioMS Medical and Mr. Laine Woollard, QC, Senior Legal Counsel of TEC Edmonton, to the
MISSISSAUGA, ON, March 10 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that it has closed its previously announced "registered direct" offering of 14,583,000 million units at an issue price of US $1.20 for gross proceeds of approximately US $17.5 million. Each unit
CALGARY, March 9 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. "In 2009, we executed on our business plan focused on preparing the
<< New Zealand researchers double collaboration with Spain and Norway
MISSISSAUGA, ON, March 8 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that the previously announced offering of approximately US$15 million has been increased to approximately US$17.5 million.
Attracts Top-Quality Management Team and Board Members CPBM: OTCBB XYI1:FRA
TSX Exchange Symbol: RVX CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), reports that in the March 5th, 2010 press release
TSX Exchange Symbol: RVX CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), at the request of the Investment Industry Regulatory
OTTAWA, March 5 /CNW Telbec/ - ImaSight Corp announces today that a proposal to creditors has been accepted, resulting in the sale of the CRD-5 drug assets to Cerenis, effective February 19, 2010. On February 24, 2009, the Corporation sought BIA (Bankruptcy and
MISSISSAUGA, ON, March 5 /CNW/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase